Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$11.39 - $13.72 $748,676 - $901,829
65,731 New
65,731 $836,000
Q3 2020

Nov 12, 2020

SELL
$10.33 - $14.49 $2.04 Million - $2.86 Million
-197,057 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$11.49 - $15.26 $3.29 Million - $4.37 Million
-286,558 Reduced 59.25%
197,057 $2.76 Million
Q1 2020

May 13, 2020

SELL
$8.11 - $15.23 $919,065 - $1.73 Million
-113,325 Reduced 18.98%
483,615 $5.69 Million
Q4 2019

Feb 12, 2020

SELL
$10.28 - $14.38 $1.35 Million - $1.88 Million
-131,000 Reduced 18.0%
596,940 $8.45 Million
Q3 2019

Nov 13, 2019

BUY
$10.05 - $14.55 $11,065 - $16,019
1,101 Added 0.15%
727,940 $7.67 Million
Q2 2019

Aug 07, 2019

SELL
$13.1 - $14.95 $3.91 Million - $4.46 Million
-298,566 Reduced 29.12%
726,839 $10.6 Million
Q1 2019

May 08, 2019

SELL
$13.69 - $20.06 $3.49 Million - $5.12 Million
-255,265 Reduced 19.93%
1,025,405 $14.4 Million
Q4 2018

Feb 12, 2019

SELL
$13.96 - $18.26 $5.04 Million - $6.6 Million
-361,364 Reduced 22.01%
1,280,670 $22.3 Million
Q3 2018

Nov 13, 2018

SELL
$13.63 - $15.7 $401,076 - $461,988
-29,426 Reduced 1.76%
1,642,034 $25 Million
Q2 2018

Aug 02, 2018

BUY
$13.44 - $17.59 $4.09 Million - $5.35 Million
304,172 Added 22.25%
1,671,460 $23.1 Million
Q1 2018

May 14, 2018

BUY
$13.8 - $16.99 $4.38 Million - $5.39 Million
317,263 Added 30.21%
1,367,288 $22.8 Million
Q4 2017

Feb 09, 2018

BUY
$11.73 - $14.75 $8.32 Million - $10.5 Million
709,250 Added 208.13%
1,050,025 $14.9 Million
Q3 2017

Nov 14, 2017

BUY
$12.06 - $14.12 $4.11 Million - $4.81 Million
340,775
340,775 $4.81 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.2B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.